Uveal Melanoma

A significant negative correlation between RiskScore and the IC50 of XMD8-85, lapatinib, roscovitine, salubrinal, bexarotene, LFM-A13, FTI-277, and TGX221 chemotherapeutic agents was further noticed. In this study, we computationally identified genes associated with both disease progression and macrophage/monocyte-related characteristics in UVM and constructed a prognostic risk model with predicted immune infiltration patterns. These findings generate testable hypotheses that may inform future experimental studies on the immune mechanisms underlying UVM.

Ipilimumab combined with nivolumab has demonstrated superior outcomes, earning a median overall survival surpassing 70 months...The advent of new ICIs, such as relatlimab, introduces additional complexities in decision-making for first-line therapy...The FDA approval of tebentafusp and lifileucel has demonstrated potential in extending the survival time of patients with metastatic uveal melanoma...It aims to facilitate informed treatment decisions and enhance understanding of the multifaceted challenges in effectively managing advanced melanoma. As new therapies emerge, continuous education and adaptability will be key to optimising patient outcomes.

Notably, early 6p gain was frequently exclusive of BAP1 aberrations and associated with a favourable prognosis, suggesting that metastatic potential in UM may be established early during tumorigenesis. Collectively, our findings provide molecular changes contributing to tumorigenesis and metastatic progression in UM and offer potential biomarkers for early detection and prognosis prediction.

This meta-analysis offers new insights into the genetic architecture of UM, highlights potential therapeutic targets, and explores the genetic relationship with CM and skin pigmentation.

This case illustrates a rare late local recurrence of choroidal melanoma with different appearance from the original tumor. It also highlights the diagnostic and prognostic role of transretinal biopsy in confirming the nature of the lesion as a recurrence and the option of proton beam radiation as salvage therapy.

In sporadic meningiomas, BAP1 alterations are rare but define an aggressive molecular subset with poor outcomes. Here, we describe a patient with BAP1-TPDS and multifocal cranial meningiomas who experienced exceptional radiographic regression of her tumors while receiving dual immune checkpoint blockade for metastatic uveal melanoma.

Analogous PAX3 positive populations were also identified in mouse and human single-cell transcriptomic datasets. Collectively, these findings establish a critical role for Mitfa-independent melanocyte progenitors in UM pathogenesis.

JPX should not be regarded as a uniformly oncogenic lncRNA. Its role appears to depend on tumor context, the dominant downstream program, and, in some settings, the status of the JPX-XIST axis. JPX is better viewed as a candidate biomarker and an experimental target than as a clinically validated one.

P1/2, N=111, Not yet recruiting, VM Discovery, Inc.

Despite advances in our understanding of the pathogenesis of glioblastoma, the mOS median overall survival in our real-world patient cohort did not improve over time. The findings emphasise the need for ongoing research efforts to improve outcomes in this lethal disease.

In human uveal melanoma, expression of the effero-score was correlated with poor survival. Therefore, Effero-seq sheds light on the molecular reprogramming induced by efferocytosis in the TME, opening previously unknown avenues for understanding macrophage function and developing targeted treatments.